Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.50 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.49 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.44 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.44 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6334117 | 0.78 | BCL2L1 (0.62) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL12123735 | 0.75 | BCL2L1 (0.59) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL5160945 | 0.75 | HDAC3 (0.53) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL1347826 | 0.75 | NPC1 (0.53) | RAB9ACNR1CNR2 | |
| SCHEMBL8290959 | 0.74 | CYP2A6 (0.47) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL4405770 | 0.74 | BCL2L1 (0.57) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL29913871 | 0.74 | BCL2L1 (0.57) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL25411197 | 0.74 | BCL2L1 (0.47) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL31130328 | 0.73 | RAB9A (0.50) | HDAC3HDAC1HDAC2RAB9AHDAC4 | |
| SCHEMBL28118458 | 0.73 | BCL2L1 (0.65) | HDAC3HDAC1HDAC2RAB9AHDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8063240-B2 | Prostaglandin E1 and E2 analogs for the treatment of various medical conditions | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2011-11-22 | — | — | US | disclosed |
| US-20090221654-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | CAYMAN CHEMICAL COMPANY (US) | 2009-09-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221654-A1 | PROSTAGLANDIN E1 AND E2 ANALOGS FOR THE TREATMENT OF VARIOUS MEDICAL CONDITIONS | PTGER1, PTGER4, PTGER2 | HDAC3 4044/4885HDAC1 3381/4885HDAC2 2609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.